NICE endorses four new devices for safer prostate cancer diagnosis

NICE (National Institute for Health and Care Excellence (London, UK)) have endorsed the use of four new devices for the diagnosis of prostate cancer in men. Current recommendations suggest MRI for first-line investigation, then a prostate biopsy to collect tissue samples for analysis if prostate cancer is still suspected. One method of collecting prostate biopsy samples, termed transrectal ultrasound guided (TRUS) biopsy, can result in serious infections including sepsis. There are two methods of collecting prostate biopsy samples for diagnosis. The first is transrectal ultrasound guided (TRUS) biopsy that collects samples with a biopsy needle inserted through the rectal wall...